Apart from PD-1 and PD-L1, other molecular targets for novel immune checkpoint inhibitors (LAG-3, TIGIT, TIM-3, and VISTA) have been discovered continuously, but remained to be tested in DLBCL (Fig. 3) [47]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.